GlaxoSmithKline LLC allegedly engaged in unfair and deceptive practices when it misrepresented the uses and qualities of its asthma drug, Advair, and antidepressant drugs, Paxil and Wellbutrin. As a result of the investigation and settlement, GSK has agreed to change the way it markets those drugs and refrain from any false, misleading or deceptive promotion of those drugs, which violated the Tennessee Consumer Protection Act. GSK has also agreed to reduce financial incentives for sales representatives to engage in deceptive marketing through at least March 2019. Tennessee worked on the leadership committee of this 45 Attorneys General multistate settlement.
This list includes only significant filings and is not intended to be a complete record of the matter.